10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2017 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 16, 2018) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Net Sales | $ 27,390 | 20,853 | 20,405 |
| Cost of products sold, excluding amortization of intangible assets | 12,337 | 9,024 | 8,747 |
| Amortization of intangible assets | 1,975 | 550 | 601 |
| Research and development | 2,235 | 1,422 | 1,405 |
| Selling, general and administrative | 9,117 | 6,672 | 6,785 |
| Total Operating Cost and Expenses | 25,664 | 17,668 | 17,538 |
| Operating Earnings | 1,726 | 3,185 | 2,867 |
| Interest expense | 904 | 431 | 163 |
| Interest income | (124) | (99) | (105) |
| Net foreign exchange (gain) loss | (34) | 495 | (93) |
| Other (income) expense, net | (1,251) | 945 | (281) |
| Earnings from Continuing Operations Before Taxes | 2,231 | 1,413 | 3,183 |
| Taxes on Earnings from Continuing Operations | 1,878 | 350 | 577 |
| Earnings from Continuing Operations | 353 | 1,063 | 2,606 |
| Earnings from Discontinued Operations, net of taxes | 124 | 321 | 65 |
| Gain on sale of Discontinued Operations, net of taxes | 16 | 1,752 | |
| Net Earnings from Discontinued Operations, net of taxes | 124 | 337 | 1,817 |
| Net Earnings | 477 | 1,400 | 4,423 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 0.20 | 0.71 | 1.73 |
| Discontinued Operations (in dollars per share) | 0.07 | 0.23 | 1.21 |
| Net Earnings (in dollars per share) | 0.27 | 0.94 | 2.94 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 0.20 | 0.71 | 1.72 |
| Discontinued Operations (in dollars per share) | 0.07 | 0.23 | 1.20 |
| Net Earnings (in dollars per share) | 0.27 | 0.94 | 2.92 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,740 | 1,477 | 1,496 |
| Dilutive Common Stock Options (in shares) | 9 | 6 | 10 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,749 | 1,483 | 1,506 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 5 | 1 | |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2017 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 16, 2018) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Net Earnings | $ 477 | 1,400 | 4,423 |
| Foreign currency translation gain (loss) adjustments | 1,365 | (130) | (2,013) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $(61) in 2017, $(125) in 2016 and $101 in 2015 | (243) | (326) | 252 |
| Unrealized gains (losses) on marketable equity securities, net of taxes of $(76) in 2017, $(28) in 2016 and $104 in 2015 | 64 | (134) | 64 |
| Net (losses) gains on derivative instruments designated as cash flow hedges, net of taxes of $(43) in 2017, $(4) in 2016 and $(9) in 2015 | (134) | (15) | (35) |
| Other Comprehensive Income (Loss) | 1,052 | (605) | (1,732) |
| Comprehensive Income | 1,529 | 795 | 2,691 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | (3,452) | (4,959) | (4,829) |
| Net actuarial (losses) and prior service (cost) and credits | (2,521) | (2,284) | (1,958) |
| Cumulative unrealized (losses) gains on marketable equity securities | (5) | (69) | 65 |
| Cumulative (losses) gains on derivative instruments designated as cash flow hedges | (84) | 49 | 64 |
| Accumulated other comprehensive income (loss) | (6,062) | (7,263) | (6,658) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2017 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 16, 2018) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 477 | 1,400 | 4,423 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 1,046 | 803 | 871 |
| Amortization of intangible assets | 1,975 | 550 | 601 |
| Share-based compensation | 406 | 310 | 292 |
| Impact of currency devaluation | 480 | ||
| Amortization of inventory step-up | 907 | ||
| Investing and financing (gains) losses, net | 47 | 86 | (18) |
| Amortization of bridge financing fees | 5 | 165 | |
| Gains on sale of businesses | (1,163) | (25) | (2,840) |
| Mylan N.V. equity investment adjustment | 947 | ||
| Gain on sale of Mylan N.V. shares | (45) | (207) | |
| Trade receivables | (207) | (177) | (171) |
| Inventories | 249 | (98) | (257) |
| Prepaid expenses and other assets | 109 | 113 | 57 |
| Trade accounts payable and other liabilities | 615 | (652) | (742) |
| Income taxes | 1,149 | (699) | 957 |
| Net Cash From Operating Activities | 5,570 | 3,203 | 2,966 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,135) | (1,121) | (1,110) |
| Acquisitions of businesses and technologies, net of cash acquired | (17,183) | (80) | (235) |
| Proceeds from business dispositions | 6,042 | 25 | 230 |
| Proceeds from the sale of Mylan N.V. shares | 2,704 | 2,290 | |
| Purchases of investment securities | (210) | (2,823) | (4,933) |
| Proceeds from sales of investment securities | 129 | 3,709 | 4,112 |
| Other | 35 | 42 | 52 |
| Net Cash From (Used in) Investing Activities | (9,618) | (248) | 406 |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | (1,034) | (1,767) | (1,281) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 6,742 | 14,934 | 2,485 |
| Repayments of long-term debt and debt with maturities over 3 months | (8,650) | (12) | (57) |
| Payment of bridge financing fees | (170) | ||
| Purchase of Alere preferred stock | (710) | ||
| Acquisition and contingent consideration payments related to business acquisitions | (13) | (25) | (17) |
| Purchases of common shares | (117) | (522) | (2,237) |
| Proceeds from stock options exercised | 350 | 248 | 314 |
| Dividends paid | (1,849) | (1,539) | (1,443) |
| Net Cash From (Used in) Financing Activities | (5,281) | 11,147 | (2,236) |
| Effect of exchange rate changes on cash and cash equivalents | 116 | (483) | (198) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (9,213) | 13,619 | 938 |
| Cash and Cash Equivalents, Beginning of Year | 18,620 | 5,001 | |
| Cash and Cash Equivalents, End of Year | 9,407 | 18,620 | 5,001 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 570 | 620 | 631 |
| Interest paid | 917 | 181 | 166 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2017 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2017 10-K (Filed: Feb 16, 2018) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2017 | Dec 31, 2016 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 9,407 | 18,620 |
| Investments, primarily bank time deposits and U.S. treasury bills | 203 | 155 |
| Trade receivables, less allowances of - 2017: $294; 2016: $250 | 5,249 | 3,248 |
| Inventories: | ||
| Finished products | 2,339 | 1,624 |
| Work in process | 472 | 294 |
| Materials | 790 | 516 |
| Total inventories | 3,601 | 2,434 |
| Other prepaid expenses and receivables | 1,667 | 1,806 |
| Current assets held for disposition | 20 | 513 |
| Total Current Assets | 20,147 | 26,776 |
| Investments | 883 | 2,947 |
| Property and Equipment, at Cost: | ||
| Land | 526 | 408 |
| Buildings | 3,613 | 2,602 |
| Equipment | 10,394 | 8,394 |
| Construction in progress | 732 | 962 |
| Property and Equipment, at cost | 15,265 | 12,366 |
| Less: accumulated depreciation and amortization | 7,658 | 6,661 |
| Net Property and Equipment | 7,607 | 5,705 |
| Intangible Assets, net of amortization | 21,473 | 4,539 |
| Goodwill | 24,020 | 7,683 |
| Deferred Income Taxes and Other Assets | 1,944 | 2,263 |
| Non-current Assets Held for Disposition | 176 | 2,753 |
| Total Assets | 76,250 | 52,666 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 206 | 1,322 |
| Trade accounts payable | 2,402 | 1,178 |
| Salaries, wages and commissions | 1,187 | 752 |
| Other accrued liabilities | 3,811 | 2,581 |
| Dividends payable | 489 | 391 |
| Income taxes payable | 309 | 188 |
| Current portion of long-term debt | 508 | 3 |
| Current liabilities held for disposition | 245 | |
| Total Current Liabilities | 8,912 | 6,660 |
| Long-term debt | 27,210 | 20,681 |
| Post-employment obligations and other long-term liabilities | 9,030 | 4,549 |
| Non-current liabilities held for disposition | 59 | |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2017: 1,965,908,188; 2016: 1,707,475,455 | 23,206 | 13,027 |
| Common shares held in treasury, at cost - Shares: 2017: 222,305,719; 2016: 234,606,250 | (10,225) | (10,791) |
| Earnings employed in the business | 23,978 | 25,565 |
| Accumulated other comprehensive income (loss) | (6,062) | (7,263) |
| Total Abbott Shareholders' Investment | 30,897 | 20,538 |
| Noncontrolling Interests in Subsidiaries | 201 | 179 |
| Total Shareholders' Investment | 31,098 | 20,717 |
| Total Liabilities and Shareholders' Investment | 76,250 | 52,666 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |